Research Article
Upregulation of NDUFAF2 in Lung Adenocarcinoma Is a Novel Independent Prognostic Biomarker
Table 1
Correlation between NDUFAF2 expression and baseline clinicopathologic characteristics of LUAD patients from the TCGA database.
| Characteristic | Low expression of NDUFAF2 | High expression of NDUFAF2 | |
| | 256 | 257 | | Age, (%) | | | 0.928 | ≤65 | 125 (24.3%) | 123 (23.9%) | | >65 | 131 (25.7%) | 134 (26.1%) | | Gender, (%) | | | 0.892 | Female | 139 (27.1%) | 137 (26.7%) | | Male | 117 (22.8%) | 120 (23.4%) | | Pathologic stage, (%) | | | <0.001 | Stage I | 156 (30.9%) | 118 (23.4%) | | Stage II | 57 (11.3%) | 64 (12.7%) | | Stage III | 26 (5.1%) | 58 (11.5%) | | Stage IV | 13 (2.6%) | 13 (2.6%) | | T stage, (%) | | | 0.002 | T1 | 102 (20%) | 66 (12.9%) | | T2 | 121 (23.7%) | 155 (30.4%) | | T3 | 24 (4.7%) | 23 (4.5%) | | T4 | 6 (1.2%) | 13 (2.5%) | | N stage, (%) | | | <0.001 | N0 | 184 (36.7%) | 146 (29.1%) | | N1 | 38 (7.6%) | 57 (11.4%) | | N2 | 24 (4.8%) | 50 (10%) | | N3 | 1 (0.2%) | 1 (0.2%) | | M stage, (%) | | | 1.000 | M0 | 165 (44.7%) | 179 (48.5%) | | M1 | 12 (3.3%) | 13 (3.5%) | | Smoker, (%) | | | 0.160 | No | 31 (6.2%) | 43 (8.6%) | | Yes | 219 (43.9%) | 206 (41.3%) | | OS event, (%) | | | 0.001 | Alive | 181 (35.3%) | 145 (28.3%) | | Dead | 75 (14.6%) | 112 (21.8%) | | Age, median (IQR) | 66 (59, 73) | 66 (59, 72) | 0.652 |
|
|